EF Hutton analyst Tony Butler initiated coverage of Replimune Group with a Buy rating and $60 price target. Replimune has three wholly-owned programs – RP1, RP2 and RP3 – and all three are in the clinic, Butler noted. Replimune is utilizing two registrational trials to build a skin cancer franchise and data from these trials will be completed in roughly 12 months, Butler tells investors.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REPL:
- Replimune Group announces inducement grants under Nasdaq listing rule
- Replimune Group appoints Chris Sarchi as CCO, Sushil Patel as CSO
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Barclays views GSK acquisition interest as positive for oncology stocks
